Review



sn38  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress sn38
    Azenosertib and sacituzumab govitecan demonstrate synergistic effects in vitro and in vivo (A) Synergy dose matrices for azenosertib and <t>SN38</t> (4-day treatment, left) or azenosertib and SG (5-day treatment, right) in MDA-MB-436 cells. ZIP synergy model is depicted, where values > 10 indicate the drug combination is synergistic, −10 to 10 indicate additivity, and <−10 indicate antagonism. SG, sacituzumab govitecan. (B) Western blot quantification of cell cycle and DNA damage proteins after treating MDA-MB-468 cells with DMSO, 650 nM azenosertib, and/or 2 nM SN38 (left), or with DMSO, 300 nM azenosertib, and/or 1 nM SG (right). TNBC, triple-negative breast cancer (C) Mean tumor volume ± SEM of MDA-MB-231 xenografts in BALB/c nude mice treated for 46 days ( n = 8/group). Percent TGI relative to vehicle control is indicated. p ≤ 0.0001 for SG and combination compared to vehicle; ∗∗∗∗ p ≤ 0.0001 for combination compared to azenosertib alone; p > 0.05 (ns) for azenosertib compared to vehicle and for combination compared to SG alone; two-way repeated measures ANOVA with Tukey’s multiple comparisons. (D) Spider plots depicting individual MDA-MB-231 tumor volumes for drug-treated group. Dotted line at 500 mm 3 indicates when tumors doubled in size relative to the starting volume. (E) Mean percent body weight change (ΔBW) ± SEM. Black dashed line indicates baseline; red dashed line indicates cutoff of −15% change. ∗ p ≤ 0.05 for combination compared to vehicle, although overall weight gain indicates good tolerability; p > 0.05 (ns) for all other group comparisons, two-way repeated measures ANOVA with Tukey’s multiple comparisons.
    Sn38, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 46 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sn+38/SN-38/pmc13285682-42-0-2
    Average 95 stars, based on 46 article reviews
    sn38 - by Bioz Stars, 2026-09
    95/100 stars

    Images

    1) Product Images from "The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads"

    Article Title: The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads

    Journal: iScience

    doi: 10.1016/j.isci.2026.116390

    Azenosertib and sacituzumab govitecan demonstrate synergistic effects in vitro and in vivo (A) Synergy dose matrices for azenosertib and SN38 (4-day treatment, left) or azenosertib and SG (5-day treatment, right) in MDA-MB-436 cells. ZIP synergy model is depicted, where values > 10 indicate the drug combination is synergistic, −10 to 10 indicate additivity, and <−10 indicate antagonism. SG, sacituzumab govitecan. (B) Western blot quantification of cell cycle and DNA damage proteins after treating MDA-MB-468 cells with DMSO, 650 nM azenosertib, and/or 2 nM SN38 (left), or with DMSO, 300 nM azenosertib, and/or 1 nM SG (right). TNBC, triple-negative breast cancer (C) Mean tumor volume ± SEM of MDA-MB-231 xenografts in BALB/c nude mice treated for 46 days ( n = 8/group). Percent TGI relative to vehicle control is indicated. p ≤ 0.0001 for SG and combination compared to vehicle; ∗∗∗∗ p ≤ 0.0001 for combination compared to azenosertib alone; p > 0.05 (ns) for azenosertib compared to vehicle and for combination compared to SG alone; two-way repeated measures ANOVA with Tukey’s multiple comparisons. (D) Spider plots depicting individual MDA-MB-231 tumor volumes for drug-treated group. Dotted line at 500 mm 3 indicates when tumors doubled in size relative to the starting volume. (E) Mean percent body weight change (ΔBW) ± SEM. Black dashed line indicates baseline; red dashed line indicates cutoff of −15% change. ∗ p ≤ 0.05 for combination compared to vehicle, although overall weight gain indicates good tolerability; p > 0.05 (ns) for all other group comparisons, two-way repeated measures ANOVA with Tukey’s multiple comparisons.
    Figure Legend Snippet: Azenosertib and sacituzumab govitecan demonstrate synergistic effects in vitro and in vivo (A) Synergy dose matrices for azenosertib and SN38 (4-day treatment, left) or azenosertib and SG (5-day treatment, right) in MDA-MB-436 cells. ZIP synergy model is depicted, where values > 10 indicate the drug combination is synergistic, −10 to 10 indicate additivity, and <−10 indicate antagonism. SG, sacituzumab govitecan. (B) Western blot quantification of cell cycle and DNA damage proteins after treating MDA-MB-468 cells with DMSO, 650 nM azenosertib, and/or 2 nM SN38 (left), or with DMSO, 300 nM azenosertib, and/or 1 nM SG (right). TNBC, triple-negative breast cancer (C) Mean tumor volume ± SEM of MDA-MB-231 xenografts in BALB/c nude mice treated for 46 days ( n = 8/group). Percent TGI relative to vehicle control is indicated. p ≤ 0.0001 for SG and combination compared to vehicle; ∗∗∗∗ p ≤ 0.0001 for combination compared to azenosertib alone; p > 0.05 (ns) for azenosertib compared to vehicle and for combination compared to SG alone; two-way repeated measures ANOVA with Tukey’s multiple comparisons. (D) Spider plots depicting individual MDA-MB-231 tumor volumes for drug-treated group. Dotted line at 500 mm 3 indicates when tumors doubled in size relative to the starting volume. (E) Mean percent body weight change (ΔBW) ± SEM. Black dashed line indicates baseline; red dashed line indicates cutoff of −15% change. ∗ p ≤ 0.05 for combination compared to vehicle, although overall weight gain indicates good tolerability; p > 0.05 (ns) for all other group comparisons, two-way repeated measures ANOVA with Tukey’s multiple comparisons.

    Techniques Used: In Vitro, In Vivo, Western Blot, Control

    Related Articles

    other:

    Article Title: Dual benefits of Xiao Chai Hu Tang and its active compounds in CPT-11 therapy: intestinal protection via barrier restoration and anti-inflammation combined with enhanced tumor apoptosis.
    Article Snippet: Ethnopharmacological relevance: Xiao Chai Hu Tang (XCHT) is a classic Chinese herbal formula traditionally used for gastrointestinal disorders.. Although XCHT alleviates irinotecan (CPT-11)-induced diarrhea, whether it confers the dual benefit of concurrently reducing intestinal toxicity and enhancing antitumor apoptosis remains

    Article Title: Transcriptomics-guided high-throughput drug screening identifies potent therapies for P53 pathway altered DIPG/DMG
    Article Snippet: The reagents SN-38 (Cat# HY-13704), Olaparib (Cat# HY-10162), SCH900776 (Cat# HY-15532), AZ20 (Cat# HY-15557), KU-55933 (Cat# HY-12016), and Adavosertib (Cat# HY-10993) were purchased from MedChemExpress.

    In Vitro:

    Article Title: Patient-derived organoids predict chemotherapy response of locally advanced gastric cancer
    Article Snippet: .. After 4 days of seeding, the medium was replaced with drug-containing medium at physiological concentrations: 5-FU (Cmax in patients = 1.7–2.4 μM, range in vitro = 0.002 to 200 μM, MCE), Oxaliplatin (Cmax in patients = 3.8–10.1 μM, range in vitro = 0.01 to 1000 μM, MCE) [ ], SN-38 (Cmax in patients is about 26 nM, range in vitro = 0.03 to 3000 nM, MCE), Epirubicin (Cmax in patients is 2 μM, range in vitro = 0.002 to 20 μM, MCE) [ ], and Paclitaxel (Cmax in patients is 0.08 μM, range in vitro = 0.08 to 800 nM, MCE) [ ]. .. Control samples were incubated with 0.1% dimethyl sulfoxide (DMSO, Beyotime Biotechnology, Shanghai, China).



    Similar Products

    sn38  (MedChemExpress)
    95
    MedChemExpress sn38
    Azenosertib and sacituzumab govitecan demonstrate synergistic effects in vitro and in vivo (A) Synergy dose matrices for azenosertib and <t>SN38</t> (4-day treatment, left) or azenosertib and SG (5-day treatment, right) in MDA-MB-436 cells. ZIP synergy model is depicted, where values > 10 indicate the drug combination is synergistic, −10 to 10 indicate additivity, and <−10 indicate antagonism. SG, sacituzumab govitecan. (B) Western blot quantification of cell cycle and DNA damage proteins after treating MDA-MB-468 cells with DMSO, 650 nM azenosertib, and/or 2 nM SN38 (left), or with DMSO, 300 nM azenosertib, and/or 1 nM SG (right). TNBC, triple-negative breast cancer (C) Mean tumor volume ± SEM of MDA-MB-231 xenografts in BALB/c nude mice treated for 46 days ( n = 8/group). Percent TGI relative to vehicle control is indicated. p ≤ 0.0001 for SG and combination compared to vehicle; ∗∗∗∗ p ≤ 0.0001 for combination compared to azenosertib alone; p > 0.05 (ns) for azenosertib compared to vehicle and for combination compared to SG alone; two-way repeated measures ANOVA with Tukey’s multiple comparisons. (D) Spider plots depicting individual MDA-MB-231 tumor volumes for drug-treated group. Dotted line at 500 mm 3 indicates when tumors doubled in size relative to the starting volume. (E) Mean percent body weight change (ΔBW) ± SEM. Black dashed line indicates baseline; red dashed line indicates cutoff of −15% change. ∗ p ≤ 0.05 for combination compared to vehicle, although overall weight gain indicates good tolerability; p > 0.05 (ns) for all other group comparisons, two-way repeated measures ANOVA with Tukey’s multiple comparisons.
    Sn38, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sn+38/SN-38/pmc13285682-42-0-2
    Average 95 stars, based on 1 article reviews
    sn38 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    sn 38  (TargetMol)
    94
    TargetMol sn 38
    Azenosertib and sacituzumab govitecan demonstrate synergistic effects in vitro and in vivo (A) Synergy dose matrices for azenosertib and <t>SN38</t> (4-day treatment, left) or azenosertib and SG (5-day treatment, right) in MDA-MB-436 cells. ZIP synergy model is depicted, where values > 10 indicate the drug combination is synergistic, −10 to 10 indicate additivity, and <−10 indicate antagonism. SG, sacituzumab govitecan. (B) Western blot quantification of cell cycle and DNA damage proteins after treating MDA-MB-468 cells with DMSO, 650 nM azenosertib, and/or 2 nM SN38 (left), or with DMSO, 300 nM azenosertib, and/or 1 nM SG (right). TNBC, triple-negative breast cancer (C) Mean tumor volume ± SEM of MDA-MB-231 xenografts in BALB/c nude mice treated for 46 days ( n = 8/group). Percent TGI relative to vehicle control is indicated. p ≤ 0.0001 for SG and combination compared to vehicle; ∗∗∗∗ p ≤ 0.0001 for combination compared to azenosertib alone; p > 0.05 (ns) for azenosertib compared to vehicle and for combination compared to SG alone; two-way repeated measures ANOVA with Tukey’s multiple comparisons. (D) Spider plots depicting individual MDA-MB-231 tumor volumes for drug-treated group. Dotted line at 500 mm 3 indicates when tumors doubled in size relative to the starting volume. (E) Mean percent body weight change (ΔBW) ± SEM. Black dashed line indicates baseline; red dashed line indicates cutoff of −15% change. ∗ p ≤ 0.05 for combination compared to vehicle, although overall weight gain indicates good tolerability; p > 0.05 (ns) for all other group comparisons, two-way repeated measures ANOVA with Tukey’s multiple comparisons.
    Sn 38, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sn+38/SN-38/pm41981190-299-5-6
    Average 94 stars, based on 1 article reviews
    sn 38 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    sn 38  (MedChemExpress)
    95
    MedChemExpress sn 38
    Azenosertib and sacituzumab govitecan demonstrate synergistic effects in vitro and in vivo (A) Synergy dose matrices for azenosertib and <t>SN38</t> (4-day treatment, left) or azenosertib and SG (5-day treatment, right) in MDA-MB-436 cells. ZIP synergy model is depicted, where values > 10 indicate the drug combination is synergistic, −10 to 10 indicate additivity, and <−10 indicate antagonism. SG, sacituzumab govitecan. (B) Western blot quantification of cell cycle and DNA damage proteins after treating MDA-MB-468 cells with DMSO, 650 nM azenosertib, and/or 2 nM SN38 (left), or with DMSO, 300 nM azenosertib, and/or 1 nM SG (right). TNBC, triple-negative breast cancer (C) Mean tumor volume ± SEM of MDA-MB-231 xenografts in BALB/c nude mice treated for 46 days ( n = 8/group). Percent TGI relative to vehicle control is indicated. p ≤ 0.0001 for SG and combination compared to vehicle; ∗∗∗∗ p ≤ 0.0001 for combination compared to azenosertib alone; p > 0.05 (ns) for azenosertib compared to vehicle and for combination compared to SG alone; two-way repeated measures ANOVA with Tukey’s multiple comparisons. (D) Spider plots depicting individual MDA-MB-231 tumor volumes for drug-treated group. Dotted line at 500 mm 3 indicates when tumors doubled in size relative to the starting volume. (E) Mean percent body weight change (ΔBW) ± SEM. Black dashed line indicates baseline; red dashed line indicates cutoff of −15% change. ∗ p ≤ 0.05 for combination compared to vehicle, although overall weight gain indicates good tolerability; p > 0.05 (ns) for all other group comparisons, two-way repeated measures ANOVA with Tukey’s multiple comparisons.
    Sn 38, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sn+38/SN-38/pm41932664-50-23-24
    Average 95 stars, based on 1 article reviews
    sn 38 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    sn 38 glucuronide  (Toronto Research Chemicals)
    94
    Toronto Research Chemicals sn 38 glucuronide
    Azenosertib and sacituzumab govitecan demonstrate synergistic effects in vitro and in vivo (A) Synergy dose matrices for azenosertib and <t>SN38</t> (4-day treatment, left) or azenosertib and SG (5-day treatment, right) in MDA-MB-436 cells. ZIP synergy model is depicted, where values > 10 indicate the drug combination is synergistic, −10 to 10 indicate additivity, and <−10 indicate antagonism. SG, sacituzumab govitecan. (B) Western blot quantification of cell cycle and DNA damage proteins after treating MDA-MB-468 cells with DMSO, 650 nM azenosertib, and/or 2 nM SN38 (left), or with DMSO, 300 nM azenosertib, and/or 1 nM SG (right). TNBC, triple-negative breast cancer (C) Mean tumor volume ± SEM of MDA-MB-231 xenografts in BALB/c nude mice treated for 46 days ( n = 8/group). Percent TGI relative to vehicle control is indicated. p ≤ 0.0001 for SG and combination compared to vehicle; ∗∗∗∗ p ≤ 0.0001 for combination compared to azenosertib alone; p > 0.05 (ns) for azenosertib compared to vehicle and for combination compared to SG alone; two-way repeated measures ANOVA with Tukey’s multiple comparisons. (D) Spider plots depicting individual MDA-MB-231 tumor volumes for drug-treated group. Dotted line at 500 mm 3 indicates when tumors doubled in size relative to the starting volume. (E) Mean percent body weight change (ΔBW) ± SEM. Black dashed line indicates baseline; red dashed line indicates cutoff of −15% change. ∗ p ≤ 0.05 for combination compared to vehicle, although overall weight gain indicates good tolerability; p > 0.05 (ns) for all other group comparisons, two-way repeated measures ANOVA with Tukey’s multiple comparisons.
    Sn 38 Glucuronide, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sn+38/SN-38+Glucuronide/pm41991640-53-29-49
    Average 94 stars, based on 1 article reviews
    sn 38 glucuronide - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    sn 38  (Tocris)
    94
    Tocris sn 38
    Azenosertib and sacituzumab govitecan demonstrate synergistic effects in vitro and in vivo (A) Synergy dose matrices for azenosertib and <t>SN38</t> (4-day treatment, left) or azenosertib and SG (5-day treatment, right) in MDA-MB-436 cells. ZIP synergy model is depicted, where values > 10 indicate the drug combination is synergistic, −10 to 10 indicate additivity, and <−10 indicate antagonism. SG, sacituzumab govitecan. (B) Western blot quantification of cell cycle and DNA damage proteins after treating MDA-MB-468 cells with DMSO, 650 nM azenosertib, and/or 2 nM SN38 (left), or with DMSO, 300 nM azenosertib, and/or 1 nM SG (right). TNBC, triple-negative breast cancer (C) Mean tumor volume ± SEM of MDA-MB-231 xenografts in BALB/c nude mice treated for 46 days ( n = 8/group). Percent TGI relative to vehicle control is indicated. p ≤ 0.0001 for SG and combination compared to vehicle; ∗∗∗∗ p ≤ 0.0001 for combination compared to azenosertib alone; p > 0.05 (ns) for azenosertib compared to vehicle and for combination compared to SG alone; two-way repeated measures ANOVA with Tukey’s multiple comparisons. (D) Spider plots depicting individual MDA-MB-231 tumor volumes for drug-treated group. Dotted line at 500 mm 3 indicates when tumors doubled in size relative to the starting volume. (E) Mean percent body weight change (ΔBW) ± SEM. Black dashed line indicates baseline; red dashed line indicates cutoff of −15% change. ∗ p ≤ 0.05 for combination compared to vehicle, although overall weight gain indicates good tolerability; p > 0.05 (ns) for all other group comparisons, two-way repeated measures ANOVA with Tukey’s multiple comparisons.
    Sn 38, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sn+38/SN+38/pm41987550-40-17-18
    Average 94 stars, based on 1 article reviews
    sn 38 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Azenosertib and sacituzumab govitecan demonstrate synergistic effects in vitro and in vivo (A) Synergy dose matrices for azenosertib and SN38 (4-day treatment, left) or azenosertib and SG (5-day treatment, right) in MDA-MB-436 cells. ZIP synergy model is depicted, where values > 10 indicate the drug combination is synergistic, −10 to 10 indicate additivity, and <−10 indicate antagonism. SG, sacituzumab govitecan. (B) Western blot quantification of cell cycle and DNA damage proteins after treating MDA-MB-468 cells with DMSO, 650 nM azenosertib, and/or 2 nM SN38 (left), or with DMSO, 300 nM azenosertib, and/or 1 nM SG (right). TNBC, triple-negative breast cancer (C) Mean tumor volume ± SEM of MDA-MB-231 xenografts in BALB/c nude mice treated for 46 days ( n = 8/group). Percent TGI relative to vehicle control is indicated. p ≤ 0.0001 for SG and combination compared to vehicle; ∗∗∗∗ p ≤ 0.0001 for combination compared to azenosertib alone; p > 0.05 (ns) for azenosertib compared to vehicle and for combination compared to SG alone; two-way repeated measures ANOVA with Tukey’s multiple comparisons. (D) Spider plots depicting individual MDA-MB-231 tumor volumes for drug-treated group. Dotted line at 500 mm 3 indicates when tumors doubled in size relative to the starting volume. (E) Mean percent body weight change (ΔBW) ± SEM. Black dashed line indicates baseline; red dashed line indicates cutoff of −15% change. ∗ p ≤ 0.05 for combination compared to vehicle, although overall weight gain indicates good tolerability; p > 0.05 (ns) for all other group comparisons, two-way repeated measures ANOVA with Tukey’s multiple comparisons.

    Journal: iScience

    Article Title: The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads

    doi: 10.1016/j.isci.2026.116390

    Figure Lengend Snippet: Azenosertib and sacituzumab govitecan demonstrate synergistic effects in vitro and in vivo (A) Synergy dose matrices for azenosertib and SN38 (4-day treatment, left) or azenosertib and SG (5-day treatment, right) in MDA-MB-436 cells. ZIP synergy model is depicted, where values > 10 indicate the drug combination is synergistic, −10 to 10 indicate additivity, and <−10 indicate antagonism. SG, sacituzumab govitecan. (B) Western blot quantification of cell cycle and DNA damage proteins after treating MDA-MB-468 cells with DMSO, 650 nM azenosertib, and/or 2 nM SN38 (left), or with DMSO, 300 nM azenosertib, and/or 1 nM SG (right). TNBC, triple-negative breast cancer (C) Mean tumor volume ± SEM of MDA-MB-231 xenografts in BALB/c nude mice treated for 46 days ( n = 8/group). Percent TGI relative to vehicle control is indicated. p ≤ 0.0001 for SG and combination compared to vehicle; ∗∗∗∗ p ≤ 0.0001 for combination compared to azenosertib alone; p > 0.05 (ns) for azenosertib compared to vehicle and for combination compared to SG alone; two-way repeated measures ANOVA with Tukey’s multiple comparisons. (D) Spider plots depicting individual MDA-MB-231 tumor volumes for drug-treated group. Dotted line at 500 mm 3 indicates when tumors doubled in size relative to the starting volume. (E) Mean percent body weight change (ΔBW) ± SEM. Black dashed line indicates baseline; red dashed line indicates cutoff of −15% change. ∗ p ≤ 0.05 for combination compared to vehicle, although overall weight gain indicates good tolerability; p > 0.05 (ns) for all other group comparisons, two-way repeated measures ANOVA with Tukey’s multiple comparisons.

    Article Snippet: SN38 , MedChemExpress , HY-13704.

    Techniques: In Vitro, In Vivo, Western Blot, Control